CLINICAL TRIALS

The University of Virginia Department of Dermatology is home to the Institute for Dermatologic Research and Advancement (IDRA), which is focused on investigator-initiated as well as commercial/industry-sponsored research endeavors.

Our goal is to first and foremost provide the most up to date dermatologic care for our patients while advancing knowledge of cutaneous disease. IDRA is actively recruiting clinical trials in psoriasis, vascular anomalies, neurocutaneous disease, procedural dermatology, cutaneous malignancy, alopecia areata, graft-versus-host disease and others.

For more information about IDRA or participation in clinical trials, please contact IDRA Research Coordinator: Lauren Kuhns at LRK9T@virginia.edu

The first arm of the trial is a split body randomized placebo-controlled trial of topical STS for small (<3 mm) calcium lesions. The second arm will be a randomized dosing interval trial of Intralesional STS for larger (>3 mm) calcium lesions, comparing weekly to monthly injections.

Actively recruiting patients for the topical (small calcinosis lesions) arm.

This is a prospective, longitudinal, observational cohort study aimed at comprehensively characterizing HS from clinical and biological perspectives with the goal of improving knowledge and treatment of patients with hidradenitis suppurativa.

Subjects will fill out a paper survey or can have the option of receiving the survey via email.

Actively recruiting during HS Clinic (Mondays).

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid.

No longer recruiting.

Subjects will be randomized to receive either upadacitinib (oral dose) or dupliumab (subcutaneous injection) to treat their Atopic Dermatitis.

No longer recruiting.

Subjects will be randomized to upadacitinib or a placebo, both taken orally daily. Must have lesions present in at least 2 distinct anatomic areas.

Actively recruiting.

Subjects will be randomized to either Izokibep or a placebo, both administered via subcutaneous injection every week.